Jazz Pharma accused of pay-for-delay deals over Xyrem
14-10-2021
Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
04-02-2021
14-08-2019
NESPIX / Shutterstock.com
Ireland-based Jazz Pharma has acquired Virginia-based Cavion in a deal that values the clinical-stage biotech company at up to $312.5 million.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Jazz Pharma, Cavion, mergers and acquisitions, M&A, biotech, neurological disorders